Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

A Disease Registry of Patients With Mantle Cell Lymphoma

The purpose of this study is to create a patient registry in order to assess treatment patterns, physician reported clinical outcomes and patient-reported health-related quality of life among patients diagnosed with Mantle Cell Lymphoma (MCL) who newly initiated a novel therapy in the past 6 months and whose treatment is ongoing at the time of enrollment.
Not Available
Not Available
Dholaria, Bhagirathbhai
Vanderbilt University
Health Services Research


18 Years
Inclusion Criteria:

Inclusion Criteria: - Patient diagnosed with Mantle Cell Lymphoma (MCL) - Informed consent for participation - Age 18 years old, as of the first observed diagnosis of MCL - Patients for whom a clinical decision has been made to initiate novel therapy in the last 6 months, limited to the following novel agent categories: - Bcl-2 inhibitors - BTK inhibitors - Immunomodulatory agents - Phosphoinositide 3-kinase inhibitors The novel agent must have been granted approval in at least one haematological cancer. Treatment must be ongoing at the time of enrollment. Exclusion Criteria: Patient is participating in a clinical study that prohibits participation in non-interventional studies, or where treatment is blinded, at the time of consent.

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: